ArticleOncotarget2016
Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.Pharmacological research · 2021Pooled it
- Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas.Journal of neuro-oncology · 2022Article
- ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage.Nature communications · 2022Article
- PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.Journal of neuro-oncology · 2022Article
- Article
- Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.The oncologist · 2020Article
- Applied precision cancer medicine in metastatic biliary tract cancer.Hepatology international · 2020Article
- T lymphocyte-targeted immune checkpoint modulation in glioma.Journal for immunotherapy of cancer · 2020Review
- Applied Precision Cancer Medicine in Neuro-Oncology.Scientific reports · 2019Article
- Sequencing and curation strategies for identifying candidate glioblastoma treatments.BMC medical genomics · 2019Article
- Profiles of brain metastases: Prioritization of therapeutic targets.International journal of cancer · 2018Article
- Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors.Medical sciences (Basel, Switzerland) · 2018Review
- Rethinking medulloblastoma from a targeted therapeutics perspective.Journal of neuro-oncology · 2018Article
- The Prognostic and Therapeutic Value of PD-L1 in Glioma.Frontiers in pharmacology · 2018Review
- Glioblastoma targeted therapy: updated approaches from recent biological insights.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- GBM-associated mutations and altered protein expression are more common in young patients.Oncotarget · 2016Article
- Hallmarks of glioblastoma: a systematic review.ESMO open · 2016Article
- Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastomas (GBM) are the most aggressive and prevalent form of gliomas with abysmal prognosis and limited treatment options. We analyzed clinically relevant molecular aberrations suggestive of response to therapies in 1035 GBM tumors. Our analysis revealed mutations in 39 genes of 48 tested. IHC revealed expression of PD-L1 in 19% and PD-1 in 46%. MGMT-methylation was seen in 43%, EGFRvIII in 19% and 1p19q co-deletion in 2%. TP53 mutation was associated with concurrent mutations, while IDH1 mutation was associated with MGMT-methylation and TP53 mutation and was mutually exclusive of EGFRvIII mutation. Distinct biomarker profiles were seen in GBM compared with WHO grade III astrocytoma, suggesting different biology and potentially different treatment approaches. Analysis of 17 metachronous paired tumors showed frequent biomarker changes, including MGMT-methylation and EGFR aberrations, indicating the need for a re-biopsy for tumor profiling to direct subsequent therapy. MGMT-methylation, PR and TOPO1 appeared as significant prognostic markers in sub-cohorts of GBM defined by age. The current study represents the largest biomarker study on clinical GBM tumors using multiple technologies to detect gene mutation, amplification, protein expression and promoter methylation. These data will inform planning for future personalized biomarker-based clinical trials and identifying effective treatments based on tumor biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.